Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Operating Leases (2019 - 2025)

Anika Therapeutics (ANIK) has disclosed Operating Leases for 7 consecutive years, with $24.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 0.76% to $24.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.2 million, a 0.76% increase, with the full-year FY2025 number at $24.2 million, up 0.76% from a year prior.
  • Operating Leases was $24.2 million for Q4 2025 at Anika Therapeutics, up from $22.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $29.7 million in Q2 2022 to a low of $18.8 million in Q1 2022.
  • A 5-year average of $24.5 million and a median of $24.7 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: surged 50.27% in 2023, then decreased 10.56% in 2025.
  • Anika Therapeutics' Operating Leases stood at $19.2 million in 2021, then skyrocketed by 49.78% to $28.8 million in 2022, then dropped by 10.07% to $25.9 million in 2023, then dropped by 7.34% to $24.0 million in 2024, then grew by 0.76% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Operating Leases are $24.2 million (Q4 2025), $22.8 million (Q3 2025), and $23.2 million (Q2 2025).